Tango Therapeutics reports 82% response rate and 88% 9‑month PFS in pancreatic cancer combo trial

Tango Therapeutics announced that its investigational PRMT5 inhibitor vopimetostat combined with Revolution Medicines’ daraxonrasib produced an objective response rate of 82% in 22 efficacy‑evaluable pancreatic cancer patients. Nine months after treatment start, 88% of those patients remained progression‑free. The company said it will begin a global, randomized registrational Phase 3 study of the combination in front‑line MTAP‑deleted pancreatic cancer in the first half of 2027.

The data triggered a sharp sell‑off in Tango’s shares, which fell between 6% and 16% in trading after the release. The decline reflects investor profit‑taking and concerns about the time horizon before a potential approval.

  • 1Objective response rate was 82% among 22 efficacy‑evaluable pancreatic cancer patients.
  • 2Nine‑month progression‑free survival rate was 88% in the same cohort.
  • 3Median follow‑up for the evaluable patients was 7.1 months.
  • 4Tango plans to start a global, randomized registrational Phase 3 trial of vopimetostat plus daraxonrasib in front‑line MTAP‑deleted pancreatic cancer in the first half of 2027.
  • 5Shares fell 6% after the data release.
  • 6Pre‑market price was down 8.88% following the announcement.

Sources